NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

神經芽腫:市場考察,流行病學,市場預測 (2027年)

Neuroblastoma - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 534794
出版日期 按訂單生產 內容資訊 英文 150 Pages
商品交期: 10個工作天內
價格
神經芽腫:市場考察,流行病學,市場預測 (2027年) Neuroblastoma - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 150 Pages
簡介

主要7個國家神經芽腫的整體罹患數,2016年推定為約1530人,同年的神經芽腫市場估算為7億3358美元。

本報告提供神經芽腫市場相關調查,提供疾病概要,主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的市場趨勢,市場規模的變化與預測(過去2年·今後10年份),總括性彙整市場成長要素及障礙分析,正在開發/已上市的治療藥的簡介,潛在成長性,目前未滿足需求等資訊。

目錄

第1章 重要洞察

第2章 神經芽腫市場概要

第3章 神經芽腫市場:市場佔有率(實際成果值)

第4章 神經芽腫市場:市場佔有率(預測值)

第5章 疾病的背景和概要

第6章 簡介

  • 神經芽腫的分期
    • 神經芽腫的國際病期分類系統(INSS)
    • 國際神經芽腫風險分類系統(INRGSS)
  • 神經芽腫的風險群
    • 徵兆與症狀
    • 危險因素
    • 病理生理學
    • 治療標的
    • 診斷

第7章 流行病學和患者人口

第8章 主要觀察

第9章 人口與預測參數

第10章 主要7個國家神經芽腫的整體罹患數

第11章 神經芽腫的流行病學:各國

  • 美國
    • 神經芽腫的整體罹患數
    • 神經芽腫的罹患率:風險群
  • 歐盟5國
    • 德國
      • 神經芽腫的罹患數
      • 神經芽腫的罹患數:風險群
    • 法國
      • 神經芽腫的罹患數
      • 神經芽腫的罹患數:風險群
    • 英國
      • 神經芽腫的罹患數
      • 神經芽腫的罹患數:風險群
    • 西班牙
      • 神經芽腫的罹患數
      • 神經芽腫的罹患數:風險群
    • 義大利
      • 神經芽腫的罹患數
      • 神經芽腫的罹患數:風險群
  • 日本
    • 神經芽腫的罹患數
    • 神經芽腫的罹患數:風險群

第12章 目前治療指南

  • 美國癌症協會(ASC)
  • 美國臨床腫瘤學會(ASCO)
  • 王立癌症研究基金(Cancer Research UK)
  • 德國兒童腫瘤·血液學會(GPOH)
  • 神經芽腫的主要6團體

第13章 已上市的治療藥

  • UNITUXIN: UNITED THERAPEUTICS CORP
    • 藥物的說明
    • 作用機制
    • 法規的里程碑
    • 安全性和有效性
    • 產品簡介
    • 副作用
  • QARZIBA: EUSA PHARMA

第14章 多元的競爭

第15章 開發中治療藥

  • NAXITAMAB:Y-MABS THERAPEUTICS INC
    • 法規的里程碑
    • 開發趨勢
    • 臨床開發
    • 臨床試驗資訊
    • 產品簡介
  • OMBURTAMAB: Y-MABS THERAPEUTICS INC
  • BEVACIZUMAB + IRINOTECAN +TEMOZOLOMIDE: GENENTECH, INC
  • MNX-100:METRONOMX
  • CPP-1X:CANCER PREVENTION PHARMACEUTICALS

第16章 神經芽腫市場分析

  • 主要的觀察
  • 主要7個國家的市場概要
  • 主要7個國家的市場規模(過去2年·今後10年)
  • 主要7個國家的市場規模:風險群
  • 主要7個國家的市場規模:治療藥物別
  • 美國
    • 市場規模
    • 市場規模:風險群
    • 市場規模:治療藥物別
  • 歐盟5國
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
  • 日本

第17章 市場促進因素

第18章 市場障礙

第19章 附錄

第20章 調查手法

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI0144

DelveInsight's "Neuroblastoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Neuroblastoma market report provides current treatment practices, emerging drugs, Neuroblastoma market share of the individual therapies, current and forecasted Neuroblastoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Neuroblastoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Neuroblastoma Disease Understanding and Treatment Algorithm

The DelveInsight Neuroblastoma market report gives a thorough understanding of the Neuroblastoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Neuroblastoma.

Treatment

It covers the details of conventional and current medical therapies available in the Neuroblastoma market for the treatment of the condition. It also provides Neuroblastoma treatment algorithms and guidelines in the United States, Europe, and Japan.

Neuroblastoma Epidemiology

The Neuroblastoma epidemiology division provide insights about historical and current Neuroblastoma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Neuroblastoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Neuroblastoma Epidemiology

The epidemiology segment also provides the Neuroblastoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Neuroblastoma Drug Chapters

Drug chapter segment of the Neuroblastoma report encloses the detailed analysis of Neuroblastoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Neuroblastoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Neuroblastoma treatment.

Neuroblastoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Neuroblastoma treatment.

Neuroblastoma Market Outlook

The Neuroblastoma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Neuroblastoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Neuroblastoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Neuroblastoma market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Neuroblastoma market in 7MM.

The United States Market Outlook

This section provides the total Neuroblastoma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Neuroblastoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Neuroblastoma market size and market size by therapies in Japan is also mentioned.

Neuroblastoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Neuroblastoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Neuroblastoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neuroblastoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Neuroblastoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Neuroblastoma emerging therapies.

Reimbursement Scenario in Neuroblastoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Neuroblastoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Neuroblastoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Neuroblastoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Neuroblastoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Neuroblastoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Neuroblastoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Neuroblastoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuroblastoma market

Report Highlights

  • In the coming years, Neuroblastoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Neuroblastoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Neuroblastoma. Launch of emerging therapies will significantly impact the Neuroblastoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neuroblastoma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Neuroblastoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Neuroblastoma Pipeline Analysis
  • Neuroblastoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Neuroblastoma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Neuroblastoma Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Neuroblastoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Neuroblastoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Neuroblastoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Neuroblastoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Neuroblastoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Neuroblastoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Neuroblastoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Neuroblastoma?
  • What is the historical Neuroblastoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Neuroblastoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neuroblastoma?
  • Out of all 7MM countries, which country would have the highest prevalent population of Neuroblastoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Neuroblastoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Neuroblastoma in the USA, Europe, and Japan?
  • What are the Neuroblastoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Neuroblastoma?
  • How many therapies are developed by each company for Neuroblastoma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Neuroblastoma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Neuroblastoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Neuroblastoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Neuroblastoma?
  • What are the global historical and forecasted market of Neuroblastoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Neuroblastoma market
  • To understand the future market competition in the Neuroblastoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Neuroblastoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Neuroblastoma market
  • To understand the future market competition in the Neuroblastoma market

Table of Contents

1. Key Insights

2. Executive Summary of Neuroblastoma

3. Competitive Intelligence Analysis for Neuroblastoma

4. Neuroblastoma: Market Overview at a Glance

  • 4.1. Neuroblastoma Total Market Share (%) Distribution in 2017
  • 4.2. Neuroblastoma Total Market Share (%) Distribution in 2030

5. Neuroblastoma: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Neuroblastoma Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Neuroblastoma Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Neuroblastoma Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Neuroblastoma Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Neuroblastoma Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Neuroblastoma Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Neuroblastoma Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Neuroblastoma Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Neuroblastoma Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Neuroblastoma Treatment and Management
  • 8.2. Neuroblastoma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Neuroblastoma Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Neuroblastoma: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Neuroblastoma Market Size in 7MM
  • 13.3. Neuroblastoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Neuroblastoma Total Market Size in the United States
    • 15.1.2. Neuroblastoma Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Neuroblastoma Total Market Size in Germany
    • 15.3.2. Neuroblastoma Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Neuroblastoma Total Market Size in France
    • 15.4.2. Neuroblastoma Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Neuroblastoma Total Market Size in Italy
    • 15.5.2. Neuroblastoma Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Neuroblastoma Total Market Size in Spain
    • 15.6.2. Neuroblastoma Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Neuroblastoma Total Market Size in the United Kingdom
    • 15.7.2. Neuroblastoma Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Neuroblastoma Total Market Size in Japan
    • 15.8.3. Neuroblastoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Neuroblastoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Neuroblastoma Epidemiology (2017-2030)
  • Table 2 : 7MM Neuroblastoma Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Neuroblastoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Neuroblastoma Epidemiology in Germany (2017-2030)
  • Table 6 : Neuroblastoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Neuroblastoma Epidemiology in France (2017-2030)
  • Table 8 : Neuroblastoma Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Neuroblastoma Epidemiology in Italy (2017-2030)
  • Table 10 : Neuroblastoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Neuroblastoma Epidemiology in Spain (2017-2030)
  • Table 12 : Neuroblastoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Neuroblastoma Epidemiology in the UK (2017-2030)
  • Table 14 : Neuroblastoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Neuroblastoma Epidemiology in Japan (2017-2030)
  • Table 16 : Neuroblastoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Neuroblastoma Epidemiology (2017-2030)
  • Figure 2 : 7MM Neuroblastoma Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Neuroblastoma Epidemiology in the United States (2017-2030)
  • Figure 4 : Neuroblastoma Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Neuroblastoma Epidemiology in Germany (2017-2030)
  • Figure 6 : Neuroblastoma Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Neuroblastoma Epidemiology in France (2017-2030)
  • Figure 8 : Neuroblastoma Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Neuroblastoma Epidemiology in Italy (2017-2030)
  • Figure 10 : Neuroblastoma Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Neuroblastoma Epidemiology in Spain (2017-2030)
  • Figure 12 : Neuroblastoma Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Neuroblastoma Epidemiology in the UK (2017-2030)
  • Figure 14 : Neuroblastoma Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Neuroblastoma Epidemiology in Japan (2017-2030)
  • Figure 16 : Neuroblastoma Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)